| Robert Orlowski | 美国MD Anderson肿瘤中心 | The future of antibody therapies and drug conjugates in multiple myeloma |
| James Chim | 香港中文大学玛丽医院 | Which is optimal as induction therapy for newly diagnosed transplant eligible myeloma? |
| Martin Tallman | Oregon Health and Science Universit | Who should still be transplanted for CML in 2015? |
| Michael Keating | 美国MD Anderson肿瘤中心 | What is optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients complet |
| Pankaj Malhotra | Postgraduate Institute of Medical Education and Research | What is the best frontline regimen for a CLL patient aged 60 who requires therapy? |
| Sergio Giralt | Memorial Sloan Kettering Cancer Center | Management of lower-risk MDS without del5q and refractory to ESAs |
| Raymond Wong | 美国MD Anderson肿瘤中心 | IPSS, DIPSS, DIPSS-Plus, MISPS, GIPSS: making sense of the tangled web of prognostic scoring systems |
| Daryl Tan | Singapore General Hospital | Radiation in Hodgkin Lymphoma – Who should get it? |
| David Ritchie | The Royal Melbourne Hospital | Clinical Trials Update: PD-1 Blockade in HL |
| F Hagemeister | Department of Hematology, H？pital Claude Huriez | Targeted therapy for Hodgkin’s Lymphoma |
| Kwong YL | Campus Virchow Klinikum, Charit
上一课 下一课
项目表
项目表
项目表
|